Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery
Alvotech (ALVO) reported third-quarter results showing a significant recovery in product and service revenue, which grew 78.3% year-over-year to $58.2 million as manufacturing supply stabilized. While nine-month total revenue declined 23% to $323.4 million due to previous production slowdowns at its Iceland facility, Adjusted EBITDA for the first nine months rose 15% to $78.3 million. The company is currently navigating a period of heavy investment and inventory buildup, with cash reserves decreasing to $61.5 million as it ramps up manufacturing capacity. Management provided FY 2026 revenue guidance of $650 million to $700 million and Adjusted EBITDA guidance of $180 million to $220 million, noting that results are likely to trend toward the lower end of these ranges.
Topics: EBITDA growth FDA approval financial guidance manufacturing expansion revenue decline